BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 26361701)

  • 21. Surveillance of Epstein-Barr virus infection as a risk factor for post-transplant lymphoproliferative disorder in pediatric renal transplant recipients.
    Köpf S; Tönshoff B
    Pediatr Nephrol; 2004 Apr; 19(4):365-8. PubMed ID: 14963763
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Asymptomatic post-transplant lymphoproliferative disorder diagnosed at one year protocol renal allograft biopsy.
    Kitajima K; Sasaki H; Koike J; Nakazawa R; Sato Y; Yazawa M; Tsuruoka K; Kawarazaki H; Imai N; Shirai S; Shibagaki Y; Chikaraishi T
    Nephrology (Carlton); 2014 Jun; 19 Suppl 3():42-4. PubMed ID: 24842822
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Heart allograft involvement with Epstein-Barr virus-associated posttransplant lymphoproliferative disorder.
    Abu-Farsakh H; Cagle PT; Buffone GJ; Bruner JM; Weilbaecher D; Greenberg SD
    Arch Pathol Lab Med; 1992 Jan; 116(1):93-5. PubMed ID: 1310382
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Current preventive strategies and management of Epstein-Barr virus-related post-transplant lymphoproliferative disease in solid organ transplantation in Europe. Results of the ESGICH Questionnaire-based Cross-sectional Survey.
    San-Juan R; Manuel O; Hirsch HH; Fernández-Ruiz M; López-Medrano F; Comoli P; Caillard S; Grossi P; Aguado JM; ;
    Clin Microbiol Infect; 2015 Jun; 21(6):604.e1-9. PubMed ID: 25686696
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Epstein-Barr virus-associated pericarditis].
    Lentini S; Klingel K; Skowasch D; Kandolf R; Bauriedel G
    Dtsch Med Wochenschr; 2001 Sep; 126(38):1043-6. PubMed ID: 11565058
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Early evidence of lymphoproliferative disorder: post-transplant monitoring of Epstein-Barr infection in adult and pediatric patients.
    Gaeta A; Nazzari C; Verzaro S; Latte MC; Fabri G; Scateni S; Raggi C; Lubrano R; Mancini C
    New Microbiol; 2006 Oct; 29(4):231-41. PubMed ID: 17201089
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Epstein-Barr virus-associated pneumonia in patients with post-transplant lymphoproliferative disease after hematopoietic stem cell transplantation.
    Liu QF; Fan ZP; Luo XD; Sun J; Zhang Y; Ding YQ
    Transpl Infect Dis; 2010 Aug; 12(4):284-91. PubMed ID: 20345506
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prospective Epstein-Barr virus-related post-transplant lymphoproliferative disorder prevention program in pediatric allogeneic hematopoietic stem cell transplant: virological monitoring and first-line treatment.
    Chiereghin A; Prete A; Belotti T; Gibertoni D; Piccirilli G; Gabrielli L; Pession A; Lazzarotto T
    Transpl Infect Dis; 2016 Feb; 18(1):44-54. PubMed ID: 26574232
    [TBL] [Abstract][Full Text] [Related]  

  • 29. EBV-positive mucocutaneous ulcer in organ transplant recipients: a localized indolent posttransplant lymphoproliferative disorder.
    Hart M; Thakral B; Yohe S; Balfour HH; Singh C; Spears M; McKenna RW
    Am J Surg Pathol; 2014 Nov; 38(11):1522-9. PubMed ID: 25007145
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Recurrent bleeding of a duodenal ulcer in a 55-year-old man after heart transplantation].
    Vogel Y; Wolff I; Zobel C; Hildenbrand R
    Internist (Berl); 2019 Mar; 60(3):298-303. PubMed ID: 30242430
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Discrimination of Epstein-Barr virus-related posttransplant lymphoproliferations from acute rejection in lung allograft recipients.
    Rosendale B; Yousem SA
    Arch Pathol Lab Med; 1995 May; 119(5):418-23. PubMed ID: 7748068
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Targeted monitoring of patients at high risk of post-transplant lymphoproliferative disease by quantitative Epstein-Barr virus polymerase chain reaction.
    Omar H; Hägglund H; Gustafsson-Jernberg A; LeBlanc K; Mattsson J; Remberger M; Ringdén O; Sparrelid E; Sundin M; Winiarski J; Yun Z; Ljungman P
    Transpl Infect Dis; 2009 Oct; 11(5):393-9. PubMed ID: 19497070
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Two rare cases of Epstein-Barr virus-associated lymphoproliferative disorders in inflammatory bowel disease patients on thiopurines and other immunosuppressive medications.
    Subramaniam K; Cherian M; Jain S; Latimer M; Corbett M; D'Rozario J; Pavli P
    Intern Med J; 2013 Dec; 43(12):1339-42. PubMed ID: 24330365
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Posttransplant Lymphoproliferative Disorder Manifesting as Intestinal Epstein-Barr Virus-Positive Anaplastic Large-Cell Lymphoma in an Adult Renal Transplant Recipient.
    Börcek P; Özdemir BH; Özgün G; Haberal M
    Exp Clin Transplant; 2016 Nov; 14(Suppl 3):64-66. PubMed ID: 27805515
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Complete immunosuppressive withdrawal as a uniform approach to post-transplant lymphoproliferative disease in pediatric liver transplantation.
    Hurwitz M; Desai DM; Cox KL; Berquist WE; Esquivel CO; Millan MT
    Pediatr Transplant; 2004 Jun; 8(3):267-72. PubMed ID: 15176965
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Epstein-Barr virus-associated post-transplant lymphoproliferative disorder presenting with skin involvement after CD34-selected autologous peripheral blood stem cell transplantation.
    Takahashi S; Watanabe D; Miura K; Ozawa H; Tamada Y; Hara K; Matsumoto Y
    Eur J Dermatol; 2007; 17(3):242-4. PubMed ID: 17478388
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Significance of Epstein-Barr virus infection in the outcome of renal transplant patients with lymphoproliferative disorders.
    Khedmat H; Alavian S; Taheri S
    Ann Transplant; 2010; 15(2):40-4. PubMed ID: 20657518
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Response to rituximab-based therapy and risk factor analysis in Epstein Barr Virus-related lymphoproliferative disorder after hematopoietic stem cell transplant in children and adults: a study from the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation.
    Styczynski J; Gil L; Tridello G; Ljungman P; Donnelly JP; van der Velden W; Omar H; Martino R; Halkes C; Faraci M; Theunissen K; Kalwak K; Hubacek P; Sica S; Nozzoli C; Fagioli F; Matthes S; Diaz MA; Migliavacca M; Balduzzi A; Tomaszewska A; Camara Rde L; van Biezen A; Hoek J; Iacobelli S; Einsele H; Cesaro S;
    Clin Infect Dis; 2013 Sep; 57(6):794-802. PubMed ID: 23771985
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A Scheduled Program of Molecular Screening for Epstein-Barr Virus Decreases the Incidence of Post-transplantation Lymphoproliferative Disease in Pediatric Liver Transplantation.
    Soriano-López DP; Alcántar-Fierros JM; Hernández-Plata JA; González-Jorge AL; Velázquez-Ramos S; Flores-Hernández MA; Fuentes V; Castañeda P; Nieto J; Sánchez JL; López B; Valencia-Mayoral P; Varela-Fascinetto G
    Transplant Proc; 2016 Mar; 48(2):654-7. PubMed ID: 27110023
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Fulminant Epstein-Barr virus (EBV)-associated T-cell lymphoproliferative disorder with hemophagocytosis following autologous peripheral blood stem cell transplantation for relapsed angioimmunoblastic T-cell lymphoma.
    Awaya N; Adachi A; Mori T; Kamata H; Nakahara J; Yokoyama K; Yamada T; Kizaki M; Sakamoto M; Ikeda Y; Okamoto S
    Leuk Res; 2006 Aug; 30(8):1059-62. PubMed ID: 16330097
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.